LemVega Capital®’s Post

MassBio bringing out the heavy hitters after lunch with a panel on attracting investment. Sage advice from Abraham (Abe) Ceesay on building a team that investors will follow, from Stan Wang, MD, PhD on starting with critical market needs, from Emma Lees on leveraging a portfolio of partnerships, and from Jacob Petersen on deeply understanding what patients want. #StateOfPossible #biotech #venturecapital #IntentionalInvestments

As announced last week, we also expanded the leadership team with Lasse H. Görlitz, Vice President of Communications, who shares, "Having been part of building startups in biotech for 20 years, it's fantastic to join Invizyne because of the immense potential of their technology. Personally, I can see how Invizyne's cell-free approach is that scalable platform that's going to impact traditional sectors like pharma and energy, in addition to facilitating many of the promising discoveries from synthetic biology. Exciting times ahead and I look forward to being part of this inspiring team of talents!" Read the full press release here: https://lnkd.in/dVVAJuYq #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF

Ajikumar Parayil, Manus CEO, Christine Santos, CTO, and Kevin J. Fox, our Head of BioManufacturing Program, discuss their key takeaways from the BioMADE 2024 Member Meeting Day 1. Aji, Christine, and Kevin all point out that this conference, which also bridges the gap between commercialization and technology, provides a space where we can forge new partnerships and start important conversations with other industry leaders, academics, and government officials about how we can work together towards a more sustainable future, using biotechnology – and accelerate the transition to bioalternatives. We look forward to continuing conversations with industry leaders about Manus and how our BioAccelerator and BioManufacturing Programs can help them accelerate the commercialization of bioalternatives – and push the U.S. bioeconomy forward. Stay tuned for more! #bioeconomy #biomanufacturing #biotechnology #syntheticbiology #MadeByManus #BioMADE #BioMADE2024

Half-year update on German biotech venture investments H1 2024 saw German biotech VC investments hit €494M, 93% of 2023's total. Big bets of €316M show trust in top-class companies. Other VC-backed firms got €178M, with sustainable food innovators gaining traction. For more info on the state of the industry as well as current trends and challenges, download the German Biotechnology Report 2024. https://go.ey.com/4ctMX31 #BioDeutschland #Biotechnology

Join us at the #BioIT World Conference on April 17, 2024, where I will be engaging in an insightful panel discussion on fostering innovation and investment in the early stages of Biotech and Bio-IT. #BioITWorld #BiotechInnovation #InvestmentInScience

New Horizons in Biotechnology (NHBT-2023) was a conference with distinguished speakers and an amazing program with many networking opportunities. A wonderful insight into the latest developments. #wastetowealth #sustainability #closedloop economy

Wishing our colleagues, partners, and clients a happy and prosperous New Year! Let's make 2024 a year of success, collaboration, and breakthroughs. Here's to a year of increased growth and new transformative partnerships. #HappyNewYear #2024goals #happynewyear2024 #lifesciences #biotechnology #innovation #clinicalresearch

Taking partnering meetings at #BIO2024?   Clarivate's tools are an industry essential for successful dealmaking.   Let's talk about your success. Book a meeting with me: https://lnkd.in/e-xJqYiZ   #BIO2024 #BIOInternational #CEO #CBO #biotechnology #licensing

Taking partnering meetings at #BIO2024? Increasing complexity and scientific novelty of the emerging R&D pipeline presents both an opportunity and a challenge for partnering. Novelty may represent tremendous potential to address unmet patient need, but novelty also means working hard to create a shared scientific understanding between partners. Often, it’s essential both for biotech teams and pharma deal leaders to find a well-matched scientific expert inside the licensing or acquiring pharma to complete the deal. Navigate your deal by leveraging the best in data and expertise. Find Clarivate's showcase at booth #4040 or book a meeting with our experts: https://lnkd.in/e-xJqYiZ #novel #biotech #pharma #partnering #licensing #mergersandacquisitions #businessdevelopment #portfoliostrategy #lifesciences #Clarivate